A. Reid

发表

Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

Johann S de Bono, Timothy A Yap, T. Yap, 2009, Clinical Cancer Research.

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Mitch Dowsett, Gerhardt Attard, Johann S de Bono, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

D. Dearnaley, C. Parker, J. Bono, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.

C. Parker, C. Cooper, C. Drake, 2012, The Lancet. Oncology.

Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer

C. Cooper, J. Bono, D. Brewer, 2012, Modern Pathology.

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice

R. Eeles, V. Khoo, C. Parker, 2022, Frontiers in Oncology.

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

J. Bono, D. Olmos, J. D. de Bono, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.

A. Ashworth, H. Gevensleben, N. Tunariu, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Abiraterone acetate is well tolerated without concomitant use of corticosteroids.

J. D. de Bono, G. Attard, A. Reid, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial involving the pharmacodynamic (PD) study of circulating tumour cells, of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), with docetaxel (D) in patients (p) with advanced cancer.

J. Spicer, A. Gualberto, J. D. de Bono, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

J. D. de Bono, M. Middleton, C. Bowen, 2008, British Journal of Cancer.

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

J. Spicer, T. Yap, A. Gualberto, 2010, British Journal of Cancer.

A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts).

H. Scher, E. Small, D. Danila, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer

N. Tunariu, D. Mukherji, D. Olmos, 2013, British Journal of Cancer.

Romidepsin (FK228), a histone deacetylase inhibitor: Final results of a phase II study in metastatic hormone refractory prostate cancer (HRPC)

C. Parker, C. Higano, W. Stadler, 2007 .

Complex patterns of ETS gene alteration arise during cancer development in the human prostate

J. Cuzick, D. Berney, P. Scardino, 2008, Oncogene.

Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.

M. Dowsett, R. Auchus, J. D. de Bono, 2012, The Journal of clinical endocrinology and metabolism.

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

J. Verweij, P. Workman, I. Judson, 2009, Molecular Cancer Therapeutics.

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

J. D. de Bono, L. Vidal, A. Reid, 2007, European journal of cancer.

Molecular Pathways Targeting the PI 3 K / AKT Pathway for the Treatment of Prostate Cancer

T. Yap, D. Sarker, J. Bono, 2009 .

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

D. Dearnaley, C. Parker, C. Cooper, 2009, Cancer research.

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

J. Cuzick, D. Berney, I. Mills, 2008, British Journal of Cancer.

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

C. Parker, J. Bono, J. D. de Bono, 2006, British Journal of Cancer.

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

W. Gerald, J. Cuzick, D. Berney, 2010, British Journal of Cancer.

Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays.

R. Eeles, Z. Kote-Jarai, C. Woodhouse, 2008, The Journal of molecular diagnostics : JMD.

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

D. Dearnaley, C. Parker, H. Scher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

D. Olmos, J. D. de Bono, G. Attard, 2009, Cancer research.

Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways

P. Workman, R. Baird, A. Reid, 2008 .

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

D. Dearnaley, C. Parker, N. Tunariu, 2015, European urology.

Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer

C. Cooper, J. Bono, D. Brewer, 2012, Modern Pathology.

A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors

A. Harris, J. Spicer, E. Bone, 2009, Clinical Cancer Research.

Cancer Therapy : Clinical A First-inMan Phase I and Pharmacokinetic Study on CHR-2797 ( Tosedostat ) , an Inhibitor of M 1 Aminopeptidases , in Patients with Advanced Solid Tumors

A. Harris, J. Spicer, E. Bone, 2009 .

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.

D. Dearnaley, C. Parker, J. Bono, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.

D. Dearnaley, C. Parker, N. Tunariu, 2016, European urology.

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

M. Dowsett, D. Dearnaley, C. Parker, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer drug resistance

J. Bono, V. Karavasilis, A. Reid, 2008 .

A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre‐clinical prostate cancer studies

V. Khoo, A. Thompson, C. Cooper, 2009, The Prostate.

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

D. Olmos, J. D. de Bono, G. Attard, 2012 .

Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (A), in castration refractory prostate cancer (CRPC) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor

M. Dowsett, D. Dearnaley, C. Parker, 2007 .

Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC)

M. Dowsett, D. Dearnaley, C. Parker, 2008 .

CYP17 inhibition as a hormonal strategy for prostate cancer

Gerhardt Attard, Elaine Barrie, J. Bono, 2008, Nature Clinical Practice Urology.

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

P. López-Casas, D. Olmos, P. Flohr, 2021, Cancers.

PEARLS – A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA‐avid pelvic and/or para-aortic lymph nodes at presentation

J. Staffurth, E. Miles, C. Cruickshank, 2022, Clinical and translational radiation oncology.

Prostate cancer’s day in the sun

D. Dearnaley, J. Bono, G. Attard, 2008, BMJ : British Medical Journal.

Pre- and post-treatment circulating tumor cell counts (CTCc) and overall survival (OS) in castration-resistant prostate cancer (CRPC): The Royal Marsden Hospital (RMH) experience

C. Parker, H. Arkenau, D. Olmos, 2008 .

An open, pharmacokinetic (PK) and mass balance study of 14C-AZD2171, incorporating DCE-CT evaluations

J. Spicer, T. Yap, A. Reid, 2007 .

J. Spicer, T. Yap, A. Gualberto, 2010, British Journal of Cancer.

Platinum Priority – Prostate Cancer

M. Sydes, D. Dearnaley, C. Parker, 2011 .

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

J. D. de Bono, G. Attard, D. Sarker, 2006, British journal of cancer.

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

G. Attard, A. Reid, J. D. de Bono, 2009, Cancer Research.

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

M. Dowsett, D. Dearnaley, C. Parker, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abiraterone acetate is well tolerated without concomitant use of corticosteroids.

J. D. de Bono, G. Attard, A. Reid, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

D. Dearnaley, C. Parker, H. Scher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour

R. Huddart, D. Nicol, A. Pearce, 2021, European urology open science.